title: Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progression.
abstract: These studies were undertaken to examine whether the presence of human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies in sera of infected individuals would alter the rate of disease progression. HIV-1-infected individuals (n = 87) were initially examined for neutralizing activity in vitro against both laboratory and tissue culture-adapted clinical heterologous HIV-1 isolates. The neutralizing activities of sera were determined by a 90% or greater reduction in HIV-1 p24 levels in vitro. In a cross-sectional analysis of all infected individuals, we observed that sera from asymptomatic individuals neutralized a significantly greater number of heterologous HIV-1 isolates than sera from symptomatic patients. Patients who could be followed up longitudinally (n = 24) were then studied to determine the impact of neutralizing antibodies on the rate of disease progression. We observed no significant difference between the numbers of HIV-1 isolates neutralized in vitro by sera from patients who remained clinically stable and by those from patients who progressed rapidly. Our data indicated that the presence or absence of neutralizing antibodies to heterologous HIV-1 isolates was not associated with the rate of disease progression.
authors.affiliation: Department of Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, Texas 78228, USA.
authors.forename: R Q
authors.initials: RQ
authors.lastname: Warren
authors.forename: M T
authors.initials: MT
authors.lastname: Wong
authors.forename: G P
authors.initials: GP
authors.lastname: Melcher
authors.forename: S P
authors.initials: SP
authors.lastname: Blatt
authors.forename: I
authors.initials: I
authors.lastname: Zapiola
authors.forename: M B
authors.initials: MB
authors.lastname: Bouzas
authors.forename: G
authors.initials: G
authors.lastname: Muchinik
authors.forename: S A
authors.initials: SA
authors.lastname: Anderson
authors.forename: R C
authors.initials: RC
authors.lastname: Kennedy
mesh_terms: D000328:Adult; D001667:Binding, Competitive / Q000276:immunology; D018450:Disease Progression; D005260:Female; D015483:HIV Antibodies / Q000096:biosynthesis / Q000097:blood*; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology*; D015528:HIV Seroprevalence; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007223:Infant; D008137:Longitudinal Studies; D008297:Male
chemical_list: D015483:HIV Antibodies